TY - T1的发作频率减少之间的关系和健康相关的生活质量Conversion-to-Monotherapy和辅助治疗试验Eslicarbazepine醋酸(P3.229) JF -神经学乔-神经学六世- 88 - 16补充SP - P3.229 AU -富尔顿·维盟-凯瑟琳·p·Anastassopoulos AU - t·克里斯托弗·邦德盟Xuezhe王盟海龙程AU -大卫·布卢姆盟乔伊斯·首页a·克莱默Y1 - 2017/04/18 UR - //www.ez-admanager.com/content/88/16_Supplement/P3.229.abstract N2 -目的:探索之间的关系(SFR)发作频率减少癫痫患者和健康相关生命质量(HRQoL)接收Eslicarbazepine醋酸(ESL)不受控制的部分性癫痫发作。背景:癫痫大大影响HRQoL与身体、心理和社会后果。1在ESL conversion-to-monotherapy试验(093 - 045/093 - 046)和辅助治疗试验(093 - 301/093 302/093 - 304)的生活质量Epilepsy-31 (QOLIE-31)在基线管理,研究结束时,(单一疗法:星期18;辅助治疗:14)。QOLIE-31分数范围从0到100分数越高表明更好的HRQoL和最小临床重要差异(MCIDs)出版。在这些试验中,SFR≥50%被认为是临床实际意义。设计/方法:协方差分析模型被开发研究最小二乘方法(lsm)≥75% - -100%的SFR & lt≥50%, 75%,在0% & lt; 50%, QOLIE-31总分≤0%和分量表,调整基线。治疗手臂,年龄、性别、种族和地区评估包含使用逐步向后消除(p> 0.15)。没有留在模型conversion-to-monotherapy病人。年龄、种族和地区仍在模型的辅助治疗的病人。结果:基线研究结束时,总分和SFR辅助治疗可用于251个conversion-to-monotherapy病人和817个病人。 Patients with ≥75% SFR had significantly higher end-of-study Total Score LSMs compared to ≤0% SFR with these differences exceeding the MCID of 5.19 (monotherapy: 70.9 vs. 62.8, difference=8.1, p<0.001; adjunctive therapy: 63.2 vs. 56.2, difference=7.0, p<0.001). Adjunctive therapy patients with ≥50% SFR also had significantly higher end-of-study Total Score LSMs compared to patients with ≤0% SFR (59.7 vs. 56.2, difference=3.5, p=0.004). Similar results were observed in all seven subscales among adjunctive therapy patients at ≥75% SFR and in five subscales among conversion-to-monotherapy patients at ≥75% SFR.Conclusions: HRQoL was significantly better among patients with 75% or greater SFR than patients with no SFR or who worsened. Additional studies are needed to understand population-level drivers of HRQoL.Study Supported by: Research funded by Sunovion Pharmaceuticals Inc.Disclosure: Dr. Velez has received personal compensation for activities with Sunovion as an employee. Dr. Anastassopoulos has received personal compensation from Covance contracted by Sunovion as an employee. Dr. Bond has received payments from Covance which was contracted by Sunovion as an employee. Dr. Wang has received personal compensation for activities with Covance as an employee. Dr. Cheng has received personal compensation for activities with Sunovian Pharmaceuticals, Inc. as an employee. Dr. Blum has received personal compensation for activities with Sunovion Pharmaceuticals Inc. as an employee. Dr. Cramer has received personal compensation for activities with Sunovion as a consultant. ER -